Pfizer is suing Metsera and Novo Nordisk over Novo's $9 billion bid to acquire Metsera, arguing significant regulatory risk ...

The top seven customers of the hard-drive company have provided purchase orders through at least the first half of next year. The company said it is on track to meet its advisor retention goals for ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a ...

Pfizer Inc. sued Metsera Inc. and rival drugmaker Novo Nordisk A/S to block the Danish company’s rival bid for the obesity ...

Shares of Novo Nordisk, the Danish maker of Ozempic and Wegovy, which had long led the weight-control drug sales, fell after analysts at brokerage Deutsche Bank said a $9 billion attempt to wrest ...

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, claiming Metsera violated its merger agreement by entertaining ...

Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, ...

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach ...

Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition ...

U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

This is read by an automated voice. Please report any issues or inconsistencies here. President Trump’s deal with Pfizer on drug prices won’t do much for American patients, but it’s great for Pfizer.